1248 Management’s Vertex Pharmaceuticals VRTX Stock Holding History

1248 Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.7K	Sell	78 -1,265	-94%	-$561K	0.02%	108
2026 Q1	$600K	Hold	1,343	–	–	0.28%	53
2025 Q4	$609K	Buy	1,343 +62	+5%	+$26.7K	0.33%	52
2025 Q3	$502K	Sell	1,281 -514	-29%	-$215K	0.28%	62
2025 Q2	$799K	Hold	1,795	–	–	0.3%	67
2025 Q1	$870K	Sell	1,795 -270	-13%	-$126K	0.37%	54
2024 Q4	$832K	Buy	+2,065	New	+$957K	0.36%	61

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

1248 Management's VRTX Position: Q2 2026 in Review

1248 Management reduced its Vertex Pharmaceuticals (VRTX) stake by 94% in Q2 2026, selling an estimated $561K and leaving 78 shares worth $38.7K. The position accounts for 0.02% of the portfolio, ranked #108.

1248 Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $870K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

1248 Management held 78 shares of Vertex Pharmaceuticals worth $38.7K as of Q2 2026.
1248 Management sold 1,265 Vertex Pharmaceuticals shares in Q2 2026, an estimated $561K.
Vertex Pharmaceuticals made up 0.02% of 1248 Management's portfolio in Q2 2026, its #108 holding.
1248 Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
1248 Management's Vertex Pharmaceuticals position peaked at $870K in Q1 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on 1248 Management's 13F filing for Q2 2026, filed 13 Aug 2026.